PURPOSE: To determine whether blocking the expression of the chemokine receptor CXCR4 using siRNA inhibits chemotactic responses of human uveal melanoma cells to liver-derived factors and prevents liver metastases. METHODS: Human uveal melanoma cells were transfected with CXCR4 siRNA or control siRNA and tested in vitro for chemotactic and invasive behavior in response to soluble factors produced by human liver cells. The effect of CXCR4 siRNA transfection on the formation of liver metastases was tested by injecting transfected melanoma cells into the spleen capsules of NOD-SCID mice, and metastases were quantified by measuring the human housekeeping gene hHPRT in livers. RESULTS: Blocking CXCR4 interaction with its ligand using anti-CXCL12 antibody resulted in a significant reduction in the chemotactic responses of uveal melanoma cells to soluble factors produced by human liver cells. Similarly, blocking CXCR4 gene expression by transfection with CXCR4 siRNA inhibited both the chemotactic and the invasive properties of uveal melanoma cells exposed to factors produced by human livers. Uveal melanoma cells transfected with CXCR4 siRNA produced fewer liver metastases than untreated uveal melanoma cells or uveal melanoma cells transfected with control siRNA. CONCLUSIONS: CXCR4 is a key chemokine receptor that may account for the organ-specific homing of human uveal melanomas to the liver, which contains significant quantities of CXCL2, the only known ligand for CXCR4. CXCR4 is a potential therapeutic target for preventing the initial establishment of liver metastases but has limited application for use in advanced liver tumors.
PURPOSE: To determine whether blocking the expression of the chemokine receptorCXCR4 using siRNA inhibits chemotactic responses of humanuveal melanoma cells to liver-derived factors and prevents liver metastases. METHODS:Humanuveal melanoma cells were transfected with CXCR4 siRNA or control siRNA and tested in vitro for chemotactic and invasive behavior in response to soluble factors produced by human liver cells. The effect of CXCR4 siRNA transfection on the formation of liver metastases was tested by injecting transfected melanoma cells into the spleen capsules of NOD-SCID mice, and metastases were quantified by measuring the human housekeeping gene hHPRT in livers. RESULTS: Blocking CXCR4 interaction with its ligand using anti-CXCL12 antibody resulted in a significant reduction in the chemotactic responses of uveal melanoma cells to soluble factors produced by human liver cells. Similarly, blocking CXCR4 gene expression by transfection with CXCR4 siRNA inhibited both the chemotactic and the invasive properties of uveal melanoma cells exposed to factors produced by human livers. Uveal melanoma cells transfected with CXCR4 siRNA produced fewer liver metastases than untreated uveal melanoma cells or uveal melanoma cells transfected with control siRNA. CONCLUSIONS:CXCR4 is a key chemokine receptor that may account for the organ-specific homing of humanuveal melanomas to the liver, which contains significant quantities of CXCL2, the only known ligand for CXCR4. CXCR4 is a potential therapeutic target for preventing the initial establishment of liver metastases but has limited application for use in advanced liver tumors.
Authors: T Koshiba; R Hosotani; Y Miyamoto; J Ida; S Tsuji; S Nakajima; M Kawaguchi; H Kobayashi; R Doi; T Hori; N Fujii; M Imamura Journal: Clin Cancer Res Date: 2000-09 Impact factor: 12.531
Authors: A Müller; B Homey; H Soto; N Ge; D Catron; M E Buchanan; T McClanahan; E Murphy; W Yuan; S N Wagner; J L Barrera; A Mohar; E Verástegui; A Zlotnik Journal: Nature Date: 2001-03-01 Impact factor: 49.962
Authors: Chih-Hung Lee; Takashi Kakinuma; Julia Wang; Hong Zhang; Douglas C Palmer; Nicholas P Restifo; Sam T Hwang Journal: Mol Cancer Ther Date: 2006-10 Impact factor: 6.261
Authors: Lei Dong; Shuo You; Qing Zhang; Satoru Osuka; Narra S Devi; Stefan Kaluz; Jalisa H Ferguson; Hua Yang; Guoliang Chen; Binghe Wang; Hans E Grossniklaus; Erwin G Van Meir Journal: Clin Cancer Res Date: 2018-12-18 Impact factor: 12.531
Authors: Haochuan Li; Jerry Y Niederkorn; Leila Sadegh; Jessamee Mellon; Peter W Chen Journal: Invest Ophthalmol Vis Sci Date: 2013-01-09 Impact factor: 4.799
Authors: Gülçin Gezgin; Mehmet Dogrusöz; T Huibertus van Essen; Wilhelmina G M Kroes; Gregorius P M Luyten; Pieter A van der Velden; Vonn Walter; Robert M Verdijk; Thorbald van Hall; Sjoerd H van der Burg; Martine J Jager Journal: Cancer Immunol Immunother Date: 2017-04-08 Impact factor: 6.968
Authors: Shanshan Tan; Hua Yang; Shenghui Xue; Jingjuan Qiao; Mani Salarian; Khan Hekmatyar; Yuguang Meng; Rao Mukkavilli; Fan Pu; Oluwatosin Y Odubade; Wayne Harris; Yan Hai; Melinda L Yushak; Vanessa M Morales-Tirado; Pardeep Mittal; Phillip Z Sun; David Lawson; Hans E Grossniklaus; Jenny J Yang Journal: Sci Adv Date: 2020-02-07 Impact factor: 14.136